Somaxon Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference and UBS Global Life Sciences Conference

SAN DIEGO, CA – September 19, 2006 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will present at the following two investment community conferences.
Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference 2006
Thursday, September 21, 2006, at 8:40 a.m. ET
Presenter: Ken Cohen, President and Chief Executive Officer
Merrill Lynch Financial Centre, London
UBS Global Life Sciences Conference
Thursday, September 28, 2006, at 1:30 p.m. ET
Presenter: Jeff Raser, Senior Vice President, Sales and Marketing
Grand Hyatt Hotel, New York City
A live webcast of the presentations will be available in the Investor Relations section of the company’s website under Event Scheduler at www.somaxon.com. The webcasts will be archived and accessible for at least 14 days.
About Somaxon Pharmaceuticals
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon’s lead product candidate, SILENOR™ (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for pathological gambling and has completed a pilot Phase 2 trial for smoking cessation.
Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.
For more information, please visit the company’s web site at www.somaxon.com.

Contact Information

Meg McGilley

Chief Financial Officer

Somaxon Pharmaceuticals

Contact via E-mail